DNM1L and cardiac hypertrophy: To gain therapeutic insights over the role of Drp1 in ISO-induced heart dysfunction, we blocked Drp1 activity in vivo by Mdivi-1 (50 mg kg−1), a compound inhibiting Drp1 activity, and found that ISO infusion-induced flash activity was decreased and cardiac hypertrophy attenuated (Fig. 8g,h).